赫赛汀联合NP(长春瑞滨+顺铂)方案治疗蒽环类耐药晚期乳腺癌的临床分析

Clinical effect of Herceptin combined with vinorelbine and cisplatin in the treatment of metastatic breast cancer patients failed to anthracycline-based chemotherapy

目的:观察赫赛汀联合NP(长春瑞滨+顺铂)方案治疗蒽环类耐药晚期乳腺癌患者的临床疗效和毒副反应。方法:32例蒽环类耐药的晚期乳腺癌患者采用赫赛汀首次剂量为8mg/kg,随后减量至6mg/kg,化疗前1天使用。长春瑞滨25mg/m2静脉滴注,第1,8天使用。顺铂80mg/m2静脉滴注,分割为1-3天使用,21天为1周期。2个周期后评价近期疗效。结果:32例患者均可评价疗效和毒副反应,其中CR 2例,PR 13例,SD 10例,PD 7例。有效率46.9%(15/32),疾病控制率78.1%(25/32)。主要毒性反应为骨髓抑制和胃肠反应。结论:赫赛汀联合NP(长春瑞滨+顺铂)方案是治疗蒽环类耐药晚期乳腺癌有效的解救方案,不良反应可耐受。

Objective：To evaluate the efficacy and toxicity of Herceptin combined with vinorelbine （NVB） and cisplatin（DDP） in treatment of metastatic breast cancer patients failed to anthracycline - based chemotherapy. Meth- ods ： All 32 metastatic breast cancer patients failed to anthracycline - based chemotherapy were treated with Herceptin combined with NP. Herceptin was used by the way of intravenous drip at the first time with a dose of 8mg/kg the day before chemotherapy, then continuous to use by the dose of 6mg/kg. Vinorelbine with a dose of 25mg/m2 was given in- travenously at the first day and the 8th day, cisplatin 80mg/m2 was given intravenously from the first day to the third day. The regiment was repeated every 21 days and the clinical response was assessed after two cycles. Results：All 32 patients could be evaluated,2 patients achieved complete response （CR）, 13 patients partial （PR）, 10 patients stable disease （SD）, and 7 patients progressive disease （PD）. The response rate was 46.9% （15/32）and the disease con- trol rate was 78.1% （25/32）. The major side effects were bone marrow suppression and gastrointestinal effects. Con- clusion ： Combined chemotherapy of Herceptin plus NP is effective and safe in the treatment of failed to anthracycline -based chemotherapy metastatic breast cancer.